NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $8.59 million during the quarter, compared to analyst estimates of $11.18 million. Synergy Pharmaceuticals had a negative net margin of 773.82% and a negative return on equity of 652.66%. Synergy Pharmaceuticals's quarterly revenue was up 776.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.30) earnings per share. View Synergy Pharmaceuticals' Earnings History.

8 Wall Street analysts have issued 1 year price objectives for Synergy Pharmaceuticals' stock. Their predictions range from $2.50 to $15.00. On average, they anticipate Synergy Pharmaceuticals' stock price to reach $8.8125 in the next twelve months. View Analyst Ratings for Synergy Pharmaceuticals.

Synergy Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totalling 62,433,759 shares, an increase of 1.6% from the April 13th total of 61,445,700 shares. Based on an average daily volume of 2,473,154 shares, the days-to-cover ratio is presently 25.2 days. Currently, 25.4% of the shares of the company are sold short.

Some companies that are related to Synergy Pharmaceuticals include Cambrex (CBM), ARMO BioSciences (ARMO), PTC Therapeutics (PTCT), Innoviva (INVA), Zogenix (ZGNX), Radius Health (RDUS), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Apellis Pharmaceuticals (APLS), Endo International (ENDP), TherapeuticsMD (TXMD), Impax Laboratories (IPXL), Theravance Biopharma (TBPH), Myovant Sciences (MYOV) and Mallinckrodt (MNK).

Press coverage about SGYP stock has trended somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a news sentiment score of 0.08 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Synergy Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.62%), Hikari Power Ltd (0.81%), JPMorgan Chase & Co. (0.74%), CVI Holdings LLC (0.72%), Schwab Charles Investment Management Inc. (0.50%) and UBS Group AG (0.47%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

SGYP stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, JPMorgan Chase & Co., BlackRock Inc., Granite Investment Partners LLC and Clear Harbor Asset Management LLC. View Insider Buying and Selling for Synergy Pharmaceuticals.

SGYP stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Millennium Management LLC, OMERS ADMINISTRATION Corp, Schwab Charles Investment Management Inc., Mackay Shields LLC, Hikari Power Ltd and MetLife Investment Advisors LLC. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGYP stock can currently be purchased for approximately $1.65.

Synergy Pharmaceuticals has a market capitalization of $404.65 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]